NASDAQ:IBIO iBio Q3 2026 Earnings Report $1.12 +0.02 (+1.35%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.10 -0.02 (-2.22%) As of 10/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast iBio EPS ResultsActual EPS-$0.07Consensus EPS -$0.06Beat/MissMissed by -$0.01One Year Ago EPSN/AiBio Revenue ResultsActual RevenueN/AExpected Revenue$0.02 millionBeat/MissN/AYoY Revenue GrowthN/AiBio Announcement DetailsQuarterQ3 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time4:00PM ETUpcoming EarningsiBio's Q1 2027 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) iBio Earnings HeadlinesiBio (NASDAQ:IBIO) and Organogenesis (NASDAQ:ORGO) Head to Head ReviewOctober 1 at 4:29 AM | americanbankingnews.comiBio, Inc. (NASDAQ:IBIO) Stock Has Consensus Price Target of $5.29September 28, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 3 at 1:00 AM | Stansberry Research (Ad)HC Wainwright & Co. initiates coverage of iBio with a buy ratingSeptember 17, 2026 | msn.comiBio to Participate in the 2026 Wells Fargo Annual Healthcare ConferenceSeptember 1, 2026 | globenewswire.comIBio Reports Wider FY '26 Loss As IBIO-600 Phase 1 For Obesity ProgressesAugust 29, 2026 | rttnews.comSee More iBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email. Email Address About iBioiBio (NASDAQ:IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify antibody candidates and optimize their properties for potential use in cancer, autoimmune, inflammatory and fibrotic diseases. iBio’s technology platform is based in part on the antibody-discovery capabilities obtained through its acquisition of RubrYc Therapeutics. The platform is designed to support target selection, antibody generation and optimization, with an emphasis on identifying antibodies that bind specific disease-related epitopes. iBio is advancing its own discovery programs while also pursuing collaborations and licensing opportunities with pharmaceutical and biotechnology companies. Historically, iBio operated as a biologics manufacturing and development company and was known for its FastPharming plant-based protein-production technology. The company has since shifted its primary focus toward artificial intelligence-enabled antibody discovery and therapeutic development. iBio is led by President and Chief Executive Officer Martin Brenner, Ph.D.View iBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
